JP2007137836A - Nutrition transfusion for peripheral vein - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a transfusion for peripheral intravenous administration in which one chamber of the plurality of chamber containers is filled with a saccharide solution and the other is filled with an amino acid, which has no danger of administering a potassium ion being an electrolytic component in a high concentration even in the case of not opening a partition in use and hardly precipitates an amino acid crystal during preservation. <P>SOLUTION: The transfusion for peripheral intravenous administration comprises an amino acid, a saccharide and an electrolyte filled in a communicatably constituted multi-chamber container in which the first chamber at an administration side to the vein is filled with an amino acid solution not containing an electrolyte, the second chamber separated from the administration side is filled with a saccharide solution containing ≤40 mEq/L potassium ion as an electrolyte, the ratio of osmotic pressure of transfusion after mixing both the solutions to that of physiological saline of ≤3 and the pH of the transfusion after the mixing is 6.0-7.2. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to an infusion solution for nutritional supplements containing a sugar, an electrolyte and an amino acid, in particular, an infusion solution for peripheral intravenous administration.

  Oral or enteral tube feeding incapable or inadequate patients, especially long-term malnutrition, muscle protein breakdown in the body caused by severe invasion, loss or deficiency of visceral proteins, immune system failure, wound When nutritional management over 2 weeks is required for the purpose of prevention and treatment of delayed healing and organ failure, a high-calorie infusion consisting of carbohydrates, electrolytes, and amino acids is generally administered from the central vein and is widely spread Has been.

  On the other hand, in order to maintain the nutritional status of patients in a relatively non-invasive or mildly invasive phase of nutritional status, infusions for peripheral vein administration are generally administered from the forearm vein or the like using a peripheral indwelling needle or the like. Yes. In recent years, the nutritional status of patients has improved, and with the development of endoscopic surgery, etc., the number of patients with a lighter degree of invasion has increased due to the development and popularization of surgical operations with less surgical invasion. The number of patients receiving peripheral intravenous fluids tends to increase.

  As a preparation used for the above nutrient solution, a product containing a sugar, an amino acid and an electrolyte that can be replenished up to 1000 Kcal per day is commercially available. As the container form, a one-chamber form (single bag preparation) is preferable from the viewpoint of medical malpractice, but a preparation stored in a duplex container is commercially available from the viewpoint of storage stability of the preparation. That is, infusion preparations containing sugars, amino acids, and electrolytes that have been housed in infusion bags having two or more rooms have appeared.

  In such an infusion preparation, in order to prevent sugar and amino acid from causing Maillard reaction, a solution consisting of a part of sugar and electrolyte component is provided in one chamber of the infusion bag, and an amino acid and electrolyte component is provided in the other chamber. Each of the remaining solutions is stored separately, and the two liquids are mixed and administered through the two chambers immediately before use.

  However, erroneous administration may occur without performing this communication operation or forgetting communication and administering only one liquid. In such a case, the liquid stored in each chamber is administered one by one, and in conventional infusion preparations, potassium ions as an electrolyte are blended in one liquid, so the potassium concentration is relatively high. A high fluid will be administered to the patient, and if the potassium concentration is excessively high, the patient may develop hyperkalemia, and in the worst case, death may occur due to cardiac arrest.

  In order to prevent such a problem, the potassium ion, which is an electrolyte component, is distributed to both the sugar solution side and the amino acid solution side, thereby reducing the risk of hyperkalemia even when administered by mistake. Has been proposed (Patent Document 1) and is already on the market. In addition, the present inventors have also included a calcium ion in the first chamber on the administration side to the vein and sugar, phosphate ion and potassium for the purpose of avoiding the risk of hyperkalemia when administered by mistake. A preparation containing an amino acid solution containing no ions and containing a sugar solution containing potassium ions and phosphate ions and not containing amino acids and calcium ions in a second chamber away from the administration side has been proposed (Patent Document 2). ).

However, in the above preparation, for example, in the preparation of Patent Document 1, an electrolyte component is further contained in a highly concentrated amino acid solution, and precipitation of amino acid crystals during storage is likely to occur. There is a need for further improvements.
Japanese Patent Application Laid-Open No. 2004-189677 Japanese Patent Application No. 2004-151371

  In view of the above-mentioned present situation, the present invention does not open the partition wall during use in a transfusion for peripheral vein administration in a multi-chamber container containing a sugar solution in one chamber of a multi-chamber container and an amino acid solution in another chamber. It is an object of the present invention to provide an infusion for peripheral venous administration that is free from the risk that potassium ions, which are electrolyte components, will be administered at a high concentration even when stored.

  As a result of intensive investigations by the inventor in order to solve such problems, the first chamber on the side of intravenous administration contains an amino acid solution that does not contain an electrolyte component other than the pH adjuster, and is separated from the side of administration. The two chambers contain potassium ions as the electrolyte, and the potassium ion concentration is set to 40 mEq / L or less, so that the first chamber is first mistakenly communicated without first communicating with the first chamber and the second chamber. Even if the sugar solution in the second chamber was injected after injecting the amino acid solution in the chamber, it was confirmed that a disorder such as hyperkalemia caused by a high concentration of potassium ions was not caused, and the present invention was completed.

  That is, the present invention is an infusion for peripheral venous administration in which amino acids, sugars and electrolytes are housed in a multi-chamber container configured to be able to communicate, and the electrolyte is provided in the first chamber having a discharge port on the administration side to the vein. Is contained in the second chamber away from the administration side, and a sugar solution containing 40 mEq / L or less of potassium ions as an electrolyte is contained in the second chamber. An infusion for peripheral vein administration, wherein the osmotic pressure ratio to water is 3 or less, and the pH of the infusion after mixing is in the range of 6.0 to 7.2.

  More specifically, the present invention is an infusion for peripheral vein administration in which the amino acid concentration of the amino acid solution is 1.0 to 5.0 w / v% as the concentration in the infusion after mixing the amino acid solution and the sugar solution. .

  More specifically, the present invention is an infusion for peripheral venous administration having a glucose concentration of 2.0 to 7.5 w / v% as sugar.

  Further, the present invention is an infusion for peripheral vein administration in which the volume ratio of the amino acid solution accommodated in the first chamber and the volume ratio of the sugar solution in the second chamber is 1: 5 to 1: 3.

Furthermore, the present invention is an infusion for peripheral vein administration in which the sugar solution further contains an electrolyte, preferably an infusion for peripheral vein administration having the following composition.
Glucose 2.0-7.5 w / v%
L-isoleucine 0.1-5.0 g / L
L-leucine 0.2-9.0 g / L
L-valine 0.2-10.0 g / L
L-lysine 0.15-6.0 g / L
L-methionine 0.1-7.0 g / L
L-Phenylalanine 0.1-7.7 g / L
L-threonine 0.1-5.0 g / L
L-tryptophan 0.02-3.0 g /
L-alanine 0.1-6.8 g / L
L-Arginine 0.1-11.3 g / L
L-aspartic acid 0.02-5.0 g / L
L-cysteine 0.01-0.7 g / L
L-glutamic acid 0.01-3.6 g / L
L-histidine 0.1-4.1 g / L
L-proline 0.1-5.9 g / L
L-serine 0.05-2.0 g / L
L-tyrosine 0.0-1.0 g / L
Glycine 0.1-5.4 g / L
Na ⁺ 20-150 mEq / L
K ^{+ 2 to} 32 mEq / L
Ca ²⁺ 1 ~ 15 mEq / L
Mg ²⁺ 0-15 mEq / L
Cl ^- 20 to 150 mEq / L
P 0 ~ 20 mmol / L
Zn ²⁺ 0-20μmol / L

Furthermore, the present invention is an infusion for peripheral intravenous administration which may contain vitamins in the above composition, and as such vitamins, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin A , vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acid, an infusion solution for peripheral intravenous administration is nicotine acids, only vitamin B ₁ as vitamins good infusion solution for peripheral intravenous administration also contain is there.

INDUSTRIAL APPLICABILITY According to the present invention, an infusion for peripheral venous administration is provided that provides an excellent nutritional effect for a patient who has a good nutritional state and is not invasive or has a low degree of invasiveness.
In particular, the infusion for peripheral vein administration of the present invention does not contain potassium ions in the first chamber on the side of intravenous administration, but is contained in the sugar solution side in which potassium ions are accommodated in the second chamber having a large volume. And, as a result of the potassium ion concentration being kept low, the first chamber amino acid solution is first injected without communication between the first chamber and the second chamber at the time of administration, and then the sugar solution in the second chamber Even in the case of injecting, no disorder such as hyperkalemia caused by administration of high concentration potassium ion occurs.

In addition, since the sugar solution and the amino acid solution are housed in separate chambers, both can be kept stable even if the pH is not particularly lowered. As a result, the pH of the infusion after mixing is close to the pH of blood. There is no worry of phlebitis.
Furthermore, since the amino acid solution does not contain any components other than the amino acid other than the pH regulator, it is possible to suppress the precipitation of amino acid crystals that are problematic during storage.

  In addition, since the sugar concentration is controlled so that the osmotic pressure ratio of the infusion solution to the physiological saline after mixing both solutions is 3 or less, vascular pain caused when a high concentration sugar solution is administered to the peripheral vein Absent.

  The sugar that can be used in the infusion solution for intravenous administration of the present invention is not particularly limited as long as it is a sugar that is usually used in infusion preparations. Examples of reducing sugars include glucose, fructose, and maltose, and examples of non-reducing sugars include trehalose, xylitol, sorbitol, and glycerin. Of these various sugars, glucose is preferably blended as sugar from the viewpoint of nutritional effect.

  In the infusion solution for intravenous administration provided by the present invention, the amino acid that can be used is not particularly limited as long as it is an amino acid usually used in infusion solutions. Specifically, L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-alanine, L-arginine, L-aspartic acid, Examples include L-cysteine, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, and glycine.

  These amino acids can be used alone or in combination of two or more, but are preferably contained in combination from the viewpoint of use in protein synthesis. Among them, L-isoleucine, L-leucine, L It is preferable to use 9 essential amino acids of valine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan and L-histidine, more preferably 9 essential amino acids and non-essential amino acids. It is preferable to use essential amino acids together.

  The composition of these amino acids may be appropriately adjusted depending on the type and condition of the patient's disease, and the amino acid composition suitable for the postoperative patient described in JP-A-60-123413 can be preferably used. Each amino acid is not necessarily used in the form of a free amino acid, and may be used in the form of an inorganic acid salt, an organic acid salt, or an ester that can be hydrolyzed in vivo. Furthermore, it may be used in the form of dipeptides in which the same or different amino acids are peptide-bonded.

  The electrolyte used in the present invention is not particularly limited as long as it is a commonly used electrolyte, and specific examples include inorganic and organic salts of sodium, potassium, calcium, magnesium, chlorine and phosphorus. About each inorganic and organic salt, the same thing as the active ingredient mix | blended with the infusion solution and enteral nutrient already marketed can be used. The electrolyte is necessary for maintaining the function of the living body and the electrolyte balance of the body fluid.

  Trace elements can also be added as an electrolyte. The trace element here is a metal element which is indispensable for a living body although it is a trace amount. Trace element supplementation is necessary not only to prevent deficiency, but also to promote protein synthesis, promote wound healing, and increase the activity of enzymes in the mitochondria. Specific examples include inorganic and organic salts of zinc, iron, manganese, copper, chromium, molybdenum, selenium, fluorine and iodine. In this case, you may mix | blend the trace element formulation marketed for high-calorie infusions. Each trace element in this case may be blended in consideration of the daily required amount.

  In the peripheral intravenous administration infusion of the present invention, the sugar solution and the amino acid solution are accommodated in a multi-chamber container partitioned by a communicating partition wall in order to avoid the Maillard reaction when sugar and amino acid are mixed. In addition, in order to cope with the unexpected situation where both solutions are not mixed before administration, the first chamber on the administration side to the vein contains an amino acid solution not containing potassium ions, and the second chamber separated from the administration side. Contains a sugar solution containing potassium ions.

  In this case, the sugar concentration is 3 or less, preferably 1 to 2.5 in terms of osmotic pressure ratio with respect to physiological saline (280 mOs / L) as an infusion preparation after mixing the amino acid solution and the sugar solution. Adjust to. Therefore, the sugar concentration is determined in consideration of the concentration after mixing and the volume of the sugar solution. For example, when glucose alone is used as the sugar, the glucose concentration in the infusion solution obtained by mixing the amino acid solution and the sugar solution is generally preferably 10 w / v% or less, more preferably 2.0 to 7.5 w / v. %, More preferably 2.0 to 5.0 w / v%.

  The potassium ion compounded in the sugar solution in the second chamber is 40 mEq / L or less, particularly preferably 30 mEq / L or less, as the concentration in the solution. Thus, by mixing potassium ions in a large-capacity sugar solution, an infusion solution with a high safety range in which potassium ions do not exceed the administration rate of 20 mEq / hour can be provided.

Moreover, in the infusion solution for peripheral vein administration of the present invention, it is preferable that phosphorus element is contained at 10 mmol / L or more.
Furthermore, in the infusion for peripheral intravenous administration of the present invention, the volume ratio of the amino acid solution accommodated in the first chamber and the sugar solution in the second chamber is preferably 1: 5 to 1: 3. In this infusion for peripheral vein administration, the second chamber is preferably provided with a mixed injection port for mixing other components immediately before administration. In the infusion solution for peripheral vein administration of the present invention, it is desirable that the sugar solution contained in the second chamber does not contain sulfite ions.

  Examples of the potassium ion source as an electrolyte component to be added to the sugar solution include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium acetate, dipotassium glycerophosphate, etc. In view of the purpose of supplying potassium, it is particularly preferable to use dipotassium hydrogen phosphate.

  As described above, the potassium ion concentration in the sugar solution is 40 mEq / L or less, in particular 30 mEq, which does not cause damage to the heart function due to high concentration potassium even if the sugar solution is administered without mixing with the amino acid solution. / L or less is preferable. In addition, it is preferable that this sugar solution does not contain a sulfite ion. When sulfite ions are not included, other components such as vitamins whose decomposition is accelerated by sulfite ions can be added as they are.

  The sugar solution is preferably adjusted to a low pH from the viewpoint of sterilization and storage stability, but it is necessary to maintain the pH of the infusion solution when mixed with the amino acid solution at a pH of 6 to 7 where phlebitis does not occur. To determine the volume of the amino acid solution. In general, the pH of the sugar solution is desirably about 5.

  On the other hand, the amino acid concentration of the amino acid solution is preferably 1 to 20 w / v%, more preferably 5 to 12 w / v%. The pH of the amino acid solution is not particularly limited, but is almost neutral, for example, around pH 6.5 to 7.4 is preferable. A small amount of sulfite ion necessary for amino acid stabilization can be added as sodium bisulfite.

  In order to adjust the pH of the sugar solution and the amino acid solution, a pH adjuster usually used in the infusion field can be used. As the pH adjusting agent, inorganic acids such as hydrochloric acid, and organic acids such as acetic acid, succinic acid succinic acid and malic acid can be used, but it is preferable to use physiological organic acids, particularly citric acid and acetic acid.

In the infusion solution for peripheral intravenous administration provided by the present invention, in addition to the above-mentioned sugar, amino acid, and electrolyte components, any components required depending on the patient's condition can be added. In particular, vitamins can be added as such components. Examples of vitamins include vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acids, nicotinic acids, etc. be able to.

By using these vitamins, it is possible to realize maintenance and improvement of nutritional status at an early stage. Vitamin B ₁ is a particularly preferred vitamin because it can increase the efficiency of sugar metabolism in vivo. Although this vitamin B ₁ is known as thiamine, thiamine derivatives such as prosultiamine, actiamine, thiamine disulfide, fursultiamine and salts thereof conventionally used for infusion are also vitamins in the present invention. Can be used as

  Vitamins preferably blended as other components are preferably added to the sugar solution when the sugar solution in the second chamber does not contain sulfite ions. Furthermore, vitamins can be accommodated in a chamber (third chamber) other than the first chamber and the second chamber, and the chamber can be partitioned so as to communicate with the first chamber and / or the second chamber. Vitamins can be stored as a solution or powder in a separate room for stability. Furthermore, trace elements and other pharmaceuticals can be placed as solutions or powders in the chambers (third chamber) other than the isolated first chamber and second chamber, if necessary.

  In order to prepare the infusion solution of the present invention, the above sugar, amino acid and electrolyte are mixed for the above purpose and dissolved in distilled water for injection or the like, or a sugar solution, amino acid solution, electrolyte solution, etc. prepared in advance. Can be prepared by a method such as mixing.

In the present invention, the infusion after mixing the sugar / electrolyte solution and the amino acid solution preferably has the following composition.
Glucose 2.0-7.5 w / v%, more preferably 2.0-5.0 w / v%
Total amino acid 1.0-5.0 w / v%

Each amino acid L-isoleucine 0.1-5.0 g / L, more preferably 0.8-5.0 g / L
L-leucine 0.2-9.0 g / L, more preferably 1.0-9.0 g / L
L-valine 0.2 to 10.0 g / L, more preferably 1.0 to 10.0 g / L
L-lysine 0.15-6.0 g / L, more preferably 0.8-6.0 g / L
L-methionine 0.1-7.0 g / L, more preferably 0.4-5.0 g / L
L-phenylalanine 0.1-7.7 g / L, more preferably 0.5-5.0 g / L
L-threonine 0.1-5.0 g / L, more preferably 0.5-5.0 g / L
L-tryptophan 0.02-3.0 g / L, more preferably 0.05-1.0 g / L
L-alanine 0.1-6.8 g / L, more preferably 0.5-5.0 g / L
L-arginine 0.1 to 11.3 g / L, more preferably 1.0 to 10.0 g / L
L-aspartic acid 0.02 to 5.0 g / L, more preferably 0.08 to 2.0 g / L
L-cysteine 0.01-0.7 g / L, more preferably 0.02-0.4 g / L
L-glutamic acid 0.01 to 3.6 g / L, more preferably 0.04 to 2.0 g / L
L-histidine 0.1-4.1 g / L, more preferably 0.3-3.0 g / L
L-proline 0.1-5.9 g / L, more preferably 0.4-5.0 g / L
L-serine 0.05-2.0 g / L, more preferably 0.1-1.0 g / L
L-tyrosine 0.0-1.0 g / L, more preferably 0.0-0.5 g / L
Glycine 0.1-5.4 g / L, more preferably 0.5-4.0 g / L

Electrolytes
Na ⁺ 20-150 mEq / L, more preferably 30-40 mEq / L
K ^{+ 2 to} 32 mEq / L, more preferably 15 to 25 mEq / L
Ca ²⁺ 1-15 mEq / L, more preferably 3-6 mEq / L
Mg ²⁺ 0-15 mEq / L, more preferably 3-6 mEq / L
Cl ^- 20 to 150 mEq / L, more preferably 30 to 60 mEq / L
P 0-20 mmol / L, more preferably 5-15 mmol / L
Zn ²⁺ 0-20 μmol / L, more preferably 2-10 μmol / L

  As an example of the administration method in the peripheral venous infusion solution provided by the present invention, administration can be performed by inserting an indwelling needle such as a surfflow needle, an injection needle, or a winged needle from any of the peripheral blood vessels. In such an administration method, continuous administration is possible, and nutritional management appropriate for recovery from surgical invasion can be performed in a state in which oral intake after light to moderate surgical invasion is not possible.

  The material constituting the main body of the infusion container in the present invention is preferably a soft resin material that is excellent in flexibility and transparency, and that does not easily break even if dropped after being stored at low temperature. Particularly preferred are those made of polyolefins usually used in medical containers. Examples of polyolefins include polymerized polymers such as polyethylene, polypropylene, poly 1-pentene, poly 4-methyl-1-pentene. As the container body, any of those obtained by blow molding, inflation or deflation molding of the resin can be used. Moreover, what formed by welding the peripheral part of two resin sheets may be used.

  In order to partition the container main body into a plurality of spaces, for example, a method of partitioning with a seal part that can be peeled off by external pressure during use and forming a plurality of spaces in the container (for example, JP-A-2-4671) It can be created using a communicating member having a thin portion that communicates by breaking (for example, Japanese Patent Laid-Open Nos. 2000-167022 and 2001-87350).

  In addition, when separating and enclosing other ingredients such as vitamins in a container, a sachet having a plurality of spaces is provided in one of the space inside the container body or the peripheral edge of the container, and stored in this sachet. be able to. At this time, it is preferable to select a material that does not easily adsorb the components to be filled as the material of the child bag. As such a material, polyfluorinated ethylene (Teflon (registered trademark), etc.) or a cyclic olefin copolymer is preferable. Can be listed.

  EXAMPLES The present invention will be described in more detail with reference to examples below, but the present invention is not limited to these examples.

Example 1:
A sugar solution and an amino acid solution were prepared as follows.
(1) Preparation of sugar solution After dissolving glucose, sodium chloride, magnesium sulfate, calcium gluconate, zinc sulfate and 30 g of citric acid in 25 L of water for injection, except for dipotassium hydrogen phosphate, dipotassium hydrogen phosphate Was dissolved and adjusted to pH 5.0 with citric acid, and water for injection was added to make the total volume 30 L to prepare a sugar solution.

(2) Preparation of Amino Acid Solution Each amino acid listed in Table 2 below was dissolved in water for injection and adjusted to pH 7.3 with glacial acetic acid to prepare 6 L of amino acid solution.

(3) Filling, sterilizing, and packaging into plastic containers Each of the prepared sugar solution and amino acid solution was filtered using a 0.2 μm membrane filter, and 400 mL of the sugar solution was made of plastic partitioned by a partition wall. The second chamber of the two-chamber container was filled. After sealing the second chamber, the first chamber of the plastic container was filled with 100 mL of the amino acid solution and sealed. The plastic container filled and sealed with both solutions was sterilized by high-pressure steam, cooled, and packaged with an oxygen scavenger and an outer packaging material.

The amount of L-cysteine and the degree of coloring immediately after the start of storage of the peripheral intravenous administration infusion prepared in the above Examples and after storage at 40 ° C. for 3 months were measured by an ultraviolet-visible absorbance method. In addition, the presence or absence of insoluble foreign matter was visually confirmed.
The results are shown in Table 3 below.

As can be seen from the results in the above table, the peripheral venous infusion solutions of the examples of the present invention contain L-cysteine at a high concentration even after storage at 40 ° C. for 3 months. Coloring was not observed. Also, no insoluble foreign matter was observed.
The pH of the mixed solution was 6.2.

As described above, according to the present invention, the storage stability of the components is good, and even if there is an unexpected situation where the sugar solution and the amino acid solution are not mixed before administration, high-concentration potassium ions are not injected, An excellent peripheral venous infusion solution free from phlebitis due to low pH can be provided.
According to the present invention, since a high concentration of potassium ions is not mistakenly administered to a patient, the patient causes hyperkalemia, and in the worst case, a peripheral that avoids the risk of reaching cardiac arrest. Intravenous infusions are provided and their industrial applicability is enormous.

Claims (9)

  A peripheral vein administration infusion containing amino acids, sugars and electrolytes in a multi-chamber container configured to communicate, wherein the first chamber having a discharge port contains an amino acid solution not containing electrolytes, In another second chamber, a sugar solution containing potassium ions of 40 mEq / L or less is accommodated as an electrolyte, the osmotic pressure ratio of the infusion solution after mixing both solutions to physiological saline is 3 or less, and An infusion for peripheral intravenous administration, wherein the pH of the infusion is in the range of 6.0 to 7.2.   The infusion solution for peripheral vein administration according to claim 1, wherein the amino acid concentration of the amino acid solution is 1.0 to 5.0 w / v% as a concentration in the infusion solution after mixing the amino acid solution and the sugar solution.   The infusion solution for peripheral vein administration according to claim 1 or 2, wherein the sugar concentration is 2.0 to 7.5 w / v% as sugar.   The infusion for peripheral vein administration according to claim 1, 2, or 3, wherein the volume ratio of the amino acid solution accommodated in the first chamber and the volume ratio of the sugar solution in the second chamber is 1: 5 to 1: 3.   The infusion solution for peripheral vein administration according to any one of claims 1 to 4, wherein the sugar solution further contains another electrolyte. The infusion for peripheral vein administration according to claim 5 having the following composition.
Glucose 2.0-7.5 w / v%
L-isoleucine 0.1-5.0 g / L
L-leucine 0.2-9.0 g / L
L-valine 0.2-10.0 g / L
L-lysine 0.15-6.0 g / L
L-methionine 0.1-7.0 g / L
L-Phenylalanine 0.1-7.7 g / L
L-threonine 0.1-5.0 g / L
L-tryptophan 0.02-3.0 g /
L-alanine 0.1-6.8 g / L
L-Arginine 0.1-11.3 g / L
L-aspartic acid 0.02-5.0 g / L
L-cysteine 0.01-0.7 g / L
L-glutamic acid 0.01-3.6 g / L
L-histidine 0.1-4.1 g / L
L-proline 0.1-5.9 g / L
L-serine 0.05-2.0 g / L
L-tyrosine 0.0-1.0 g / L
Glycine 0.1-5.4 g / L
Na ⁺ 20-150 mEq / L
K ^{+ 2 to} 32 mEq / L
Ca ²⁺ 1 ~ 15 mEq / L
Mg ²⁺ 0-15 mEq / L
Cl ^- 20 to 150 mEq / L
P 0 ~ 20 mmol / L
Zn ²⁺ 0-20μmol / L   The infusion for peripheral vein administration according to any one of claims 1 to 6, further comprising vitamins. The vitamin is vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acid, nicotinic acid 4. An infusion for peripheral vein administration. Infusion solution for peripheral intravenous administration according to claim 7 vitamins are vitamin B _1.